Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

cobweb icon Archived: Breast Cancer: Medications for Risk Reduction

Original Release Date: September 2013

This version of this topic is currently archived and inactive. It should be used for historical purposes only.

Archived: Recommendation Summary

PopulationRecommendationGrade
(What's This?)
Women, Increased Risk for Breast Cancer

The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene. 

B
Women, Not at Increased Risk for Breast Cancer

The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer. 

D

Go to the Clinical Considerations for additional information about risk factors.

Archived: Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

 
Current as of: September 2013

Internet Citation: Final Update Summary: Breast Cancer: Medications for Risk Reduction. U.S. Preventive Services Task Force. September 2016.
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction?ds=1&s=breast cancer medications

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857